Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

PharmaSGP Holding SE, DE000A2P4LJ5

PharmaSGP Holding SE, DE000A2P4LJ5

31.03.2021 - 07:33:27

PharmaSGP: Revenue growth in 2020 despite declining markets

fell by 26.3% in 2020 to ?16.5 million (previous year: ?22.4 million). This corresponds to an adjusted EBIT margin measured against revenue of 26.1% (previous year: 35.8%). Unadjusted EBIT amounted to ?14.2 million, corresponding to an EBIT margin of 22.5%.

Nevertheless, Michael Rudolf, CFO of PharmaSGP, sees good growth opportunities in all target markets in the medium and long term: "Structural trends such as the increasing age of the population, continuously rising health awareness or the trend towards natural drugs and self-medication favour demand for our products. Furthermore, we have a business model that allows us to react quickly to structural and demand-related market changes. We plan to take advantage of these opportunities and significantly accelerate our growth rate through M&A activities, driving growth of established brands and products through our PharmaSGP platform."

In 2021, the further course of the Covid-19 pandemic is a key factor for the performance of PharmaSGP. Based on the continued lockdown situations and current signs of a strong third wave of infections, PharmaSGP does not anticipate a general economic recovery in the first two quarters of 2021. Looking at the relevant European OTC markets, PharmaSGP expects year-on-year growth in the second half of the year at the earliest. Against this background, the Management Board forecasts total revenue of between ?56 million and ?60 million for 2021, with stable to slightly positive development of the 'Health Brands' category and an expected decline in the 'Beauty' business. The adjusted EBIT margin is expected to increase to 27-30%. The forecast does not take into account possible acquisitions.

PharmaSGP will publish its full statement for the 2020 financial year on 22 April 2021, in the 'Publications' section of the company's website ir.sgp-pharma.com.OVERVIEW OF PRELIMINARY FIGURES, YEAR-ON-YEAR COMPARISON

Group key figures (in ? million) 2019 2020 ? Revenues 62.6 63.2 1.1% Adjusted1 EBIT 22.4 16.5 -26.3% Unadjusted EBIT 22.4 14.2 -36.4% Adjusted1 EBIT margin 35.8% 26.1% ? Unadjusted EBIT margin 35.8% 22.5% ? ? ? ? ? Revenues by region (in ? million) 2019 2020 ? Germany 45.8 43.4 -5.3 % Italy 7.4 8.8 19.8 % Other European countries 9.4 11.0 17.7 % ? ? ? ? Share of revenues by region 2019 2020 ? Germany 73.2% 68.6% ? Italy 11.8% 14.0% ? Other European countries 15.0% 17.4% ? ? ? ? ? Revenues by product category (in ? million) 2019 2020 ? Health Brands 49.0 54.8 11.8% Beauty Brands 13.0 8.4 -35.2% ? ? ? ? ?

[1] The one-off costs and special effects amount to ?2.3 million and include, among other things, costs of the corporate and organizational structuring of the PharmaSGP Group as well as legal and consulting costs in connection with planned acquisitions.


cometis AG Claudius Krause Phone: +49-611-20585528 Email: ir@sgp-pharma.com


PharmaSGP is a leading consumer health company focusing on non-prescription pharmaceuticals sold over the counter ("OTC"). PharmaSGP's products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and fewer known side-effects than most chemical-based pharmaceuticals.

The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic, chemical-free pain remedies with its brand families RubaXX(R) for rheumatic pain and Restaxil(R) for neuralgic pain (nerve pain). PharmaSGP also offers leading products against sexual weakness and vertigo. Since the launch of the first product from the current portfolio in Germany in 2012, we have successfully exported our business model to other European countries such as Austria, Italy, Belgium, Spain and France.

PharmaSGP generated revenues of ?62.6 million at an EBIT margin of 26.1% in 2020.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, leverage established brand families to introduce new chemical-free OTC and other healthcare products, increase PharmaSGP's European footprint, and accelerate its growth strategy by capitalizing on selected M&A opportunities.


31.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: PharmaSGP Holding SE Lochhamer Schlag 21 82166 Gr?felfing

Germany E-mail: ir@sgp-pharma.com Internet: https://pharmasgp.com ISIN: DE000A2P4LJ5 WKN: A2P4LJ Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich EQS News ID: 1179866 ? End of News DGAP News Service


@ dgap.de